A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Pharmacokinetic Characteristics Between Rosuvastatin 20mg and Ezetimibe 10mg co-administration and Rosuvastatin/Ezetimibe complex product in Healthy Male Korean Subjects

Trial Profile

A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Pharmacokinetic Characteristics Between Rosuvastatin 20mg and Ezetimibe 10mg co-administration and Rosuvastatin/Ezetimibe complex product in Healthy Male Korean Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Ezetimibe (Primary) ; Ezetimibe/rosuvastatin (Primary) ; Rosuvastatin (Primary)
  • Indications Hypercholesterolaemia
  • Focus Pharmacokinetics
  • Acronyms ID-ROEZ-101
  • Sponsors Ildong Pharmaceutical
  • Most Recent Events

    • 06 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top